Motif Bio PLC Director/PDMR Shareholding (4111U)

TIDMMTFB

RNS Number : 4111U

Motif Bio PLC

18 January 2017

18 January 2017

Motif Bio plc

("Motif Bio" or the "Company")

Grant of share options to PDMR

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has granted a total of 1,500,000 options to purchase ordinary shares of 1 pence each of Motif Bio ("Ordinary Shares") to Robert Dickey IV, Chief Financial Officer. The options vest over a four year period and have an exercise price of 25.5 pence per Ordinary Share, being the closing price of the Ordinary Shares on 17 January 2017, the date of grant of the options.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 
 
 1       Details of the person discharging managerial responsibilities/person closely associated 
------  ----------------------------------------------------------------------------------------------- 
 a)      Name                                        Robert Dickey IV 
------  ------------------------------------------  --------------------------------------------------- 
 2       Reason for the notification 
------  ----------------------------------------------------------------------------------------------- 
                                                     Chief Financial Officer, PDMR 
 a)       Position/status 
------  ------------------------------------------  --------------------------------------------------- 
 b)      Initial notification/Amendment              Initial Notification 
------  ------------------------------------------  --------------------------------------------------- 
 3       Details of the issuer, emission allowance market participant, auction platform, auctioneer 
          or auction monitor 
------  ----------------------------------------------------------------------------------------------- 
 a)      Name                                        Motif Bio Plc 
------  ------------------------------------------  --------------------------------------------------- 
 b)      LEI                                         54930080DN00QTIUUU84 
------  ------------------------------------------  --------------------------------------------------- 
 4       Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
          each type of transaction; (iii) each date; and (iv) each place where transactions have been 
          conducted 
------  ----------------------------------------------------------------------------------------------- 
 a)      Description of the                          Ordinary Shares 
          financial instrument, 
          type of instrument                          ISIN GB00BVVT4H71 
 
          Identification code 
------  ------------------------------------------  --------------------------------------------------- 
 b)      Nature of the transaction                   Grant of options to purchase 1,500,000 
                                                      Ordinary Shares 
------  ------------------------------------------  --------------------------------------------------- 
 c)      Price(s) and volume(s)                       Price(s)    Volume(s) 
                                                      ----------  ---------- 
                                                       N/A         1,500,000 
                                                      ----------  ---------- 
------  ------------------------------------------  --------------------------------------------------- 
 d)      Aggregated information                       Price(s)    Volume(s) 
                                                      ----------  ---------- 
                                                       N/A         1,500,000 
                                                      ----------  ---------- 
------  ------------------------------------------  --------------------------------------------------- 
 e)      Date of the transaction                     17 January 2017 
------  ------------------------------------------  --------------------------------------------------- 
 f)      Place of the transaction                    N/A 
------  ------------------------------------------  --------------------------------------------------- 
 
 

For further information please contact:

 
 Motif Bio plc                                                  [e-mail] 
  Graham Lumsden (Chief 
  Executive Officer) 
 Zeus Capital Limited (NOMAD 
  & BROKER) 
  Phil Walker/Giles Balleny 
  Dominic Wilson                                              [phone] 
 Northland Capital Partners 
  Limited (BROKER) 
  Patrick Claridge/David 
  Hignell 
  John Howes/Rob Rees (Broking)                               [phone] 
 Walbrook PR Ltd. (FINANCIAL       [phone] or [e-mail] 
  PR & IR)                                               Mob: [phone] 
  Paul McManus                                           Mob: [phone] 
  Mike Wort 
 
 MC Services AG (EUROPEAN 
  IR) 
 Raimund Gabriel                                               [phone] 
 

Notes to Editors:

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (Revive 1 and Revive 2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHEAEFXFFDXEAF

(END) Dow Jones Newswires

January 18, 2017 02:05 ET (07:05 GMT)